WMT + CAT: Pharmacy's Future?
Yesterday, Wal-Mart Stores (
Well, I can’t resist pointing out that my January post Wal-Mart's PBM Game Plan predicted Wal-Mart’s strategy. Give the post another read because the economic logic is still generally accurate, plus there is a good discussion in the comments below the post.
HERE COME RESTRICTED NETWORKS
Note that Wal-Mart is not giving these drugs away, despite the Reuter’s statement that Wal-Mart “will fill certain generic drugs for free.” Only the co-pay for beneficiaries is $0 -- the same as your Drug Channels subscription fee. Caterpillar’s health plan still pays for the drugs, but now negotiates directly with Wal-Mart rather than using a PBM intermediary.
This is precisely the “restricted network” trade-off that I described in my January post:
- Give your beneficiaries freedom of pharmacy choice and pay $X for drugs.
- Restrict choice to a more efficient channel, e.g., Wal-Mart pharmacies, and pay less than $X.
Restricting the network to Wal-Mart pharmacies won’t work in many geographies, limiting the impact on urban/suburban chain pharmacies such as Walgreens (
COMPETITIVE IMPACT
As I see it, the deal does not represent a direct frontal assault on PBMs such as Express Scripts (
I’m more intrigued by the competitive comparison with
Final thought: The economics of the branded drug supply chain make it essentially impossible for Wal-Mart to offer the same deal for drugs with marketing exclusivity – for now. I expect that barrier to fall within the next few years.






9 comments:
To post anonymously, select "Guest" and enter "Anonymous" as your name. Your email will NOT be published.